Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
Radiopharmaceutical therapeutics are becoming an increasingly important oncology sector, shaped by growing pipelines and emerging alpha-emitter innovation despite supply constraints.
EGFR therapies evolved through multiple generations to 2026, transforming major cancers, while this review summarizes resistance, diagnostics, and six future priorities.
A comprehensive review summarizes 2021–2026 advances showing how genetic, environmental, immune, and microbial factors drive CD and UC pathogenesis, while highlighting ongoing refractory disease and the need for precision-medicine translation.
The gut microbiome is increasingly linked to metabolic disease, but clinical translation remains early and inconsistent.
A concise overview of how ADCs have evolved clinically and technologically, highlighting pivotal approvals, resistance mechanisms and emerging strategies such as novel payloads, smarter linkers, and combination regimens.
A clinician-focused overview of approved Pompe disease ERTs, summarizing key trial evidence, real-world outcomes and treatment strategies across infantile- and late-onset disease.
Semaglutide offers substantial clinical benefits, yet understanding how to monitor and manage adverse effects is key to safe use.
This review outlines the epidemiology and evidence-based management of menopausal vasomotor symptoms, emphasizing individualized treatment and emerging nonhormonal options.
This review summarizes current treatments and emerging drug development strategies in schizophrenia.
The ALPK1 clinical studies are early but advancing, led by Drug Farm with dual agonist and inhibitor programs targeting inflammatory, infectious, and rare genetic diseases.
Recent advances in Nipah virus immunity and pathogenesis reveal key immunological gaps limiting rational vaccine and therapeutic design.
In 2025, TNBC was redefined by first-line TROP2 ADC breakthroughs, delivering major PFS/OS results and accelerating regulatory.
This review outlines key clinical breakthroughs, regulatory milestones, and next-generation innovations shaping CAR-T therapy in hematologic malignancies from 2021–2026.